Clinical experiences with G17DT in gastrointestinal malignancies

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 487-492

  He, Aiwu R ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Clinical trials; G17DT; Gastroentestinal cancer

Indexed keywords

ANTIBODY CONJUGATE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; G17 GASTRIN DIPHTHERIA TOXOID ANTIBODY CONJUGATE; GASTRIN; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; CANCER VACCINE; GASTRIN IMMUNOGEN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; GENE TARGETING; HUMAN; HUMORAL IMMUNITY; INJECTION PAIN; INJECTION SITE ABSCESS; INJECTION SITE DISCOMFORT; INJECTION SITE SWELLING; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REVIEW; STOMACH ADENOCARCINOMA; ANIMAL; CONTROLLED CLINICAL TRIAL; GASTROINTESTINAL TUMOR; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CANCER VACCINES; GASTRINS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOCONJUGATES; RANDOMIZED CONTROLLED TRIALS;

EID: 33746313200     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.487     Document Type: Review

References (41)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 55, 891-903 (1993).
2. Jemal A, Murray T, Ward W et al. Cancer statistics. CA Cancer J. Clin. 55, 10-30 (2005).
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 71, 587-591 (1995).
4. Wagner AD, Grothe W, Behl S et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 18 (2), CD004064 (2005).
5. Lacave AJ, Wils J, Diaz-Rubio E et al. cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A Phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur. J. Cancer Clin. Oncol. 21, 1321-1324 (1985).
6. Aabo K, Pedersen H, Rorth M. Cisplatin in the treatment of advanced gastric carcinoma: a Phase II study. Cancer Treat. Rep. 69, 449-450 (1985).
7. Moiseyenko V, Ajani J, Tjulandin SA et al. Final results of a randomized controlled Phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J. Clin. Oncol. 22, 3080s (2005) (Abstract).
8. Ajani JA, Baker J, Pisters PW et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a Phase II study. Cancer 94, 641-646 (2002).
9. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 22, 658-663 (2004).
10. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12, 29-34 (1994).
11. Rocha Lima CM, Rotche R, Jeffery M et al. A randomized Phase III study comparing efficacy and safety of gemcitabine and irinotecan to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc. Am. Soc. Clin. Oncol. 22, 251a (2003) (Abstract).
12. Ryan DP, Kulke MH, Fuchs CS et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94, 97-103 (2002).
13. Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol. 6, 369-376 (2005).
14. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23, 3509-3516 (2005).
15. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. 22, 2610-2616 (2004).
16. Moore M, Goldstein D, Hamm J et al. Erlotinib plus compared to gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCNC-CTG). J. Clin. Oncol. 23, 1s (2005) (Abstract).
17. Kobori O, Vuillot MT, Martin F. Growth response of rat stomach cancer cells to gastro-entero-pancreatic hormones. Int. J. Cancer 30, 65-67 (1982).
18. Ochai A, Yasui W, Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J. Cancer Res. 76, 1064-1071 (1985).
19. Watson S, Durrant L, Morris S. Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br. J. Cancer 59, 554-558 (1989).
20. Moyer MP, Armstrong A, Aust JB et al. Effects of gastrin, glutamine and somatostatin on the in vitro growth of normal and malignant human gastric mucosal cells. Arch. Sung. 121, 258-258 (1986).
21. Rengifo-Cam W, Singh P. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. Curr. Pharm. Des. 10(19), 2345-2358 (2004).
22. Kelly A, Hollande F, Shulkes A, Baldwin GS. Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines. J. Gastroenterol. Hepatol. 13, 208 (1998).
23. Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 265, 410-412 (1994).
24. Wang TC, Koh TJ, Varro A et al. Porcessing and proliferative effects of human progastrin in transgenic mice. J. Clin. Invest. 8, 1918-1929 (1996).
25. Stepan VM, Sawada M, Yamada T et al. Glycine-extednded gastrin exerts growth-promoting effects on colon cancer cell lines. Gastroenterology 110, A1122 (1996).
26. Iwase K, Evers BM, Hellmich MR et al. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 113, 78-90 (1997).
27. Watson SA, Gilliam AD. G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin. Biol. Ther. 1(2), 309-317 (2001).
28. Gastrin 17 vaccine - Aphton: anti-gastrin 17 immunogen, G17DT. Bio. Drugs 17(3), 223-225 (2003).
29. Watson SA, Michaeli D, Grimes S, Morris T et al. Gastimmune rasises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 56, 880-885 (1996).
30. Watson SA, Michael D, Justin TA, Grimes S et al. Pre-clinical evaluation of the gastrimmune immunogen alone and in combination with 5-Fluorouracil/leucovorin in a rat colorectal cancer model. Int. J. Cancer 75, 873-877 (1998).
31. Watson SA, Michael D, Grimes S, Morris TM et al. A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice. Int. J. Cancer 81, 248-254 (1999).
32. Watson SA, Morris TM, Varro A, Michaeli D, Smith AM. A comparison of the therapeutic effectiveness of gastrin neutralization in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 45, 812-817.
33. Broome P, Gilliam AD, Watson SA, Iftikhar S, Welch N, Michaeli D. Phase II studies of G17DT in advanced gastric carcinoma. J. Clin. Oncol. 2002 ASCO, FL, USA, 20(18S), 2309 (2002).
34. Hecht JR, Ajani JA, Michaeli D. A multicenter Phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease. J. Clin. Oncol. 2003 ASCO 21(10S), 1035 (2003).
35. Gilliam AD, Watson SA, Henwood M, McKenzie AJ et al. A Phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol. 30, 536-543 (2004).
36. Brett BT, Smith SC, Bouvier CV, Michaeli D et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20(20), 4225-4231 (2002).
37. Gilliam AD, Henwood M, Watson SA et al. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma. J. Clin. Oncol. 2001 ASCO, Annual Meeting Proceedings, CA, USA, 19(18S), 533 (2001).
38. Gilliam AD, Topuzov EG, Garin AM et al. Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings, LA, USA, 22(14S), 2511 (2004).
39. Shapiro J, Marshall J, Karasek P et al. G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J. Clin. Oncol. 2005 ASCO Annual Meeting Proceedings, FL, USA, 23(18S), LBA4012 (2005).
40. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Cancer Res. 6, 4719-4724 (2000).
41. Rocha Lima CM, Buck R, Meyer K et al. A multicenter Phase II study of irinotecan in combination with G17DT immunogen in subjects with metastatic colorectal adenocarcinoma (CRC) refractory to previous irinotecan-based chemotherapy. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings, LA, USA, 22(14S), 3573 (2004).